Influence of lovastatin on BCL-2 and bax expression by plasma cells and T lymphocytes in short-term cultures of multiple myeloma bone marrow mononuclear cells

Polish Journal of Pharmacology

Volumn 56, Issue 4, 2004, Pages 485-489

  Dmoszyńska, Anna ^a   Podhorecka, Monika ^a   Roliński, Jacek ^a   Soroka Wojtaszko, Maria ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Apoptosis; BAX; BCL 2; Lovastatin; Plasma cells; T lymphocytes

Indexed keywords

MEVINOLIN; PROTEIN BAX; PROTEIN BCL 2; UBIQUINONE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; MONONUCLEAR CELL; MULTIPLE MYELOMA; MYOPATHY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BONE MARROW; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BCL-2; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; MULTIPLE MYELOMA; PLASMA CELLS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 9744250226     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Agarwal B, Bhendwal S, Halmos B, Moss SF, Ramey WG., Holt PR: Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin Cancer Res, 1999, 5, 2223-2229.
2. Dmoszyńska A, Roliński J, Bojarska-Junak A, Manko J, Jawniak D, Walter-Croneck A, Soroka-Wojtaszko M et al.: Influence of thalidomide on BCL-2 expression and proangiogenic cytokine levels in short-term culture of peripheral blood and bone marrow mononuclear cells of multiple myeloma patients. Pol J Pharmacol, 2001, 53, 709-713.
3. Feleszko W, Bałkowiec E, Sieberth E., Marczak M, Dabrowska A, Giermasz A, Czajka A et al.: Lovastatin and TNFα exhibit potentiated antitumor effects against Ha-ras transformed murine tumor via inhibition of tumor-induced angiogenesis. Int J Cancer, 1999, 81, 560-567.
4. Feleszko W, Młynarczyk J, Balkiewiec-Iskra EZ, Cajak A, Switaj T, Stoklosa T, Giermasz A et al.: Lovastatin potentiates antitumor activity and atenuates cardiotoxicity of doxorubicin in three tumor models in mice. Clin Cancer Res, 2000, 6, 2044-2052.
5. Lishner M, Bar-Sef A, Elis A, Fabian I: Effect of simvastatin alone and in combination with cytosine arabinoside on the proliferation of myeloid leukemia cell lines. J Investig Med, 2001, 49, 319-324.
6. Maltese WA: 3-Hydroxy-3-mediylglutaryl-coenzyme A reductase in human brain tumors. Neurology, 1983, 33, 1294-1299.
7. Thibault A, Samid D, Tompkims AC: Phase I study of lovastatin an inhibitor of the mevalonate pathway in patients with cancer. Clin Cancer Res, 1996, 2, 483-491.
8. Van de Donk NW, Kamphuis MM, Lokhorst HM, Bloem AC: The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells. Leukemia, 2002, 16, 1362-1371.
9. Weis M, Heeschen C, Glassford AJ, Cooke JP: Statins have biphasic effects on angiogenesis. Circulation, 2002, 105, 739-748.